Drug Trial Radar · NCT06502379
A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Dec 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
147
Actual
Start
Aug 2, 2024
Primary completion
Jun 1, 2025
Study completion Nov 15, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of AZD8965 via single and multiple ascending doses in healthy participants (including Japanese and Chinese participants), and to assess the effect of food on the safety, tolerability, and PK of orally administered AZD8965.
Conditions
- Healthy Participants
Interventions
AZD8965Drug
AZD8965 will be administered orally.
PlaceboOther
Placebo will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts 1 and 3A: Number of participants with adverse events (AEs) and serious adverse events (SAEs)Time frame: SAEs: From Screening (Day -28) to 5 weeks; AEs: From Day 1 to 5 weeks
- Parts 2 and 3B: Number of participants with AEs and SAEsTime frame: SAEs: From Screening (Day -28) to 8 weeks; AEs: From Day 1 to 8 weeks.
- Part 4: Maximum observed drug concentration (Cmax)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
- Part 4: Area under concentration-time curve from time 0 to infinity (AUCinf)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
- Part 4: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
- Part 4: Time to reach maximum observed concentration (tmax)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
- Part 4: Partial area under the concentration-time curve from time t1 to time t2 [AUC(t1-t2)]Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
- Part 4: Terminal elimination half-life (t½λz)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
- Part 4: Mean Residence Time (MRTinf)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
- Part 4: Apparent total body clearance (CL/F)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
- Part 4: Apparent volume of distribution based on the terminal (Vz/F)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
- Part 4: Accumulation ratio for AUC (Rac AUC)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
- Part 4: Accumulation ratio for Cmax (Rac Cmax)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
- Part 4: Individual and cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1-t2)]Time frame: From Day 1 (pre-dose) to Day 5
- Part 4: Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 [fe(t1-t2)]Time frame: From Day 1 (pre-dose) to Day 5
- Part 4: Relative bioavailability calculated as test AUC/reference AUC (Frel AUC)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
- Part 4: Relative bioavailability calculated as test Cmax/reference Cmax (Frel Cmax)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
- Part 4: Renal clearance (CLR)Time frame: From Day 1 (pre-dose) to Day 5
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.